Page 7 - Flipbook

Phase 3 MAGNITUDE study: First results of niraparib (NIRA)

with abiraterone acetate and prednisone (AAP) as first-line

therapy in patients (pts) with metastatic castration-resistant

prostate cancer (mCRPC) with and without homologous

recombination repair (HRR) gene alterations

3
4
2
5
Kim N. Chi, Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, 6
1
8
Ji Youl Lee, Eric J. Small, Andrea J. Pereira de Santana Gomes, Guilhem Roubaud, 10 Marniza Saad, 11
7
9
Bogdan Zurawski, 12 Valerii Sakalo, 13 Gary E. Mason, Adam del Corral, 15 George Wang, 14 Daphne Wu, 16 The QR code is intended for
14
use in the US and Canada
17
Brooke Diorio, Angela Lopez-Gitlitz, 16 Shahneen Sandhu 18 only. Copies of this slide
deck obtained through Quick
Response (QR) Code are for
personal use only and may
2
1 University of British Columbia, BC Cancer – Vancouver Center, Vancouver, BC, Canada; Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA; not be reproduced without
3 Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA; Houston Methodist Cancer Center, Houston, TX, USA; University College London, permission from ASCO® or
4
5
7
London, UK; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Department of the author of this slide deck.
6
Urology Cancer Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; Helen Diller Family Comprehensive Cancer Center, University of California San
8
11
10
9
Francisco, San Francisco, CA, USA; Liga Norte Riograndense Contra o Câncer, Natal, Brazil; Department of Medical Oncology, Institut Bergonié, Bordeaux, France; Department of
12
Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Outpatient Chemotherapy, Professor Franciszek Lukaszczyk Oncology Center,
13
Bydgoszcz, Poland; Kyiv City Clinical Oncology Center, Kyiv, Ukraine; Janssen Research & Development, Spring House, PA, USA; Janssen Research & Development, Bridgewater,
14
15
NJ, USA; Janssen Research & Development, Los Angeles, CA, USA; Janssen Research & Development, Titusville, NJ, USA; Peter MacCallum Cancer Center and the University of
17
18
16
Melbourne, Melbourne, Australia
PRESENTED BY: Kim N. Chi, MD